Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity - Evaluation of a new, fully automated non-radiometric assay

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 505-510

  Von Euler, Henrik P ^a   Rivera, Patricio ^a   Aronsson, Anne Charlotte ^b   Bengtsson, Christer ^c   Hansson, Lars Olof ^c   Eriksson, Staffan K ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b Diasorin SpA   (Italy)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Canine; Chemotherapy; Hematological malignancy; Prognosticate; Thymidine kinase 1; Tumor marker

Indexed keywords

DOXORUBICIN; LOMUSTINE; THYMIDINE KINASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; IMMUNOASSAY; INFLAMMATORY DISEASE; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY; RADIOMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DOG DISEASES; DOGS; LEUKEMIA; LYMPHOMA; NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 64549139397     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000175     Document Type: Article

References (28)

1. Welin M, Kosinska U, Mikkelsen NE, et al: Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci USA 101: 17970-17975, 2004.
2. Al-Madhoun AS, Tjarks W and Eriksson S: The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem 4: 341-350, 2004.
3. Eriksson S, Munch-Petersen B, Johansson K and Eklund H: Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 59: 1327-1346, 2002.
4. Ke PY and Chang ZF: Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24: 514-526, 2004.
5. Hengstschlager M, Knofler M, Mullner EW, Ogris E, Wintersberger E and Wawra E: Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 269: 13836-13842, 1994.
6. Gronowitz JS, Hagberg H, Kallander CF and Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487-495, 1983.
7. Hallek M, Wanders L, Strohmeyer S and Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5, 1992.
8. Poley S, Stieber P, Nussler V, Pahl H and Fateh-Moghadam A: Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17: 3025-3029, 1997.
9. Nakamura N, Momoi Y, Watari T, Yoshino T, Tsujimoto H and Hasegawa A: Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci 59: 957-960, 1997.
10. Von Euler H, Einarsson R, Olsson U, Lagerstedt AS and Eriksson S: Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med 18: 696-702, 2004.
11. Von Euler HP, Ohrvik AB and Eriksson SK: A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. Res Vet Sci 80: 17-24, 2006.
12. Öhrvik A, Lindh M, Einarsson R, Grassi J and Eriksson S: Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin Chem 50: 1597-606, 2004.
13. Paoloni M and Khanna C: Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156, 2008.
14. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al: Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819, 2005.
15. Karlsson EK, Baranowska I, Wade CM, et al: Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet 39: 1321-1328, 2007.
16. Salmon Hillbertz NH, Isaksson M, Karlsson EK, et al: Duplication of FGF3, FGF4, FGF19 and ORAOV1 causes hair ridge and predisposition to dermoid sinus in Ridgeback dogs. Nat Genet 39: 1318-1320, 2007.
17. Vail DM and MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792, 2000.
18. Knapp DW and Waters DJ: Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today 3: 8-11, 1997.
19. Hahn KA, Bravo L, Adams WH and Frazier DL: Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8: 133-143, 1994.
20. MacEwen EG: Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 9: 125-136, 1990.
21. Von Euler H, Khoshnoud R, He Q, et al: Time-dependent RNA degradation affecting cDNA array quality in spontaneous canine tumours sampled using standard surgical procedures. Int J Mol Med 16: 979-985, 2005.
22. Sueiro FA, Alessi AC and Vassallo J: Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. J Comp Pathol 131: 207-213, 2004.
23. Teske E: Canine malignant lymphoma: a review and comparison with human non-Hodgkin's lymphoma. Vet Q 16: 209-219, 1994.
24. Fenske J, Tuttle A, Olson G, Aronsson A-C and Schmidt J: Development of an automated non-radiometric assay for the thymidine kinase on the Liaison analyzer-Technical and Clinical evaluation. Tumor Biol 28 (Suppl. 1): 56, 2007.
25. Owen LN: Ch 9. Lymphoid and haematopoietic tissues (including lymphosarcoma of skin). In: TNM Classification of Tumours in Domestic Animals. Owen LN (ed.) World Health Organization, Geneva, pp46-47, 1980.
26. Piek CJ, Rutteman GR and Teske E: Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Vet Q 21: 44-49, 1999.
27. Bland JM and Altman DG: Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 346: 1085-1087, 1995.
28. Arner ES and Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155-186, 1995.